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Abstract
Background: We studied patients treated with radical cystectomy for locally advanced bladder cancer to compare
the results of both preoperative positron emission tomography/computed tomography (PET/CT) and conventional
CT with the findings of postoperative histopathological evaluation of lymph nodes.
Methods: Patients who had bladder cancer and were candidates for cystectomy underwent preoperative PET/CT
using 18-fluorodeoxyglucose (FDG) and conventional CT. The results regarding lymph node involvement were
independently evaluated by two experienced radiologists and were subsequently compared with histopathology
results, the latter of which were reassessed by an experienced uropathologist (HO).
Results: There were 54 evaluable patients (mean age 68 years, 47 [85 %] males and 7 [15 %] females) with pT and
pN status as follows: < pT2-14 (26 %), pT2-10 (18 %), and > pT2-30 (56 %); pN0 37 (69 %) and pN+ 17 (31 %). PET/CT
showed positive lymph nodes in 12 patients (22 %), and 7 of those cases were confirmed by histopathology; the
corresponding results for conventional CT were 11 (20 %) and 7 patients (13 %), respectively. PET/CT had 41 %
sensitivity, 86 % specificity, 58 % PPV, and 76 % NPV, whereas the corresponding figures for conventional CT were
41 %, 89 %, 64 %, and 77 %. Additional analyses of the right and left side of the body or in specified anatomical
regions gave similar results.
Conclusions: In this study, PET/CT and conventional CT had similar low sensitivity in detecting and localizing
regional lymph node metastasis in bladder cancer.
Background
Accurate clinical staging of localized or regionally ad-
vanced urinary bladder cancer remains a challenge.
Lymph node (LN) metastasis is correlated with de-
creased overall survival (OS), and it is plausible that sur-
vival in patients with or without such metastasis can be
improved by LN dissection [1–5]. Also, patients with LN
involvement may be candidates for preoperative chemo-
therapy if considered for cystectomy [6–10]. Preopera-
tive staging of regional LNs has relied on radiological
imaging to identify nodes that meet anatomical criteria.
Conventional computed tomography (CT) and magnetic
resonance imaging (MRI) are frequently employed as
diagnostic tools for staging in evaluation of muscle-
invasive bladder cancer. Both these methods use LN size
as a criterion for diagnosis and false-negative rates can
be as high as 40 % [11–13]. Thus there is a need for a
non-invasive imaging modality that can achieve more ac-
curate preoperative staging of bladder cancer.
Positron emission tomography/CT (PET/CT) is an ap-
proach in which the capacity to detect specific metabolic
tissue changes is combined with simultaneous accurate
anatomical depiction. Possible limitations of this com-
bined technique are that the optimal isotope for study-
ing bladder cancer has not yet been determined, and
most isotopes have a short half-life and hence require
use of an on-site cyclotron or a sophisticated transport
modality [14, 15].
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Most malignant tumors are characterized by elevated
glucose metabolism [16, 17], and therefore increased cell
proliferation in tumors can be imaged by PET/CT as in-
creased uptake of 18-fluorodeoxyglucose (FDG). FDG is
currently the only isotope approved by the US Food and
Drug Administration for use in clinical oncology. FDG has
a relatively short half-life (110 min), and it is excreted by
the kidneys and accumulated in the urinary tract, which
makes it difficult to study the urinary system in detail
[18, 19]. Nevertheless, FDG is still the isotope that is
most widely used to investigate bladder cancer [14].
In the present study, patients treated by radical cystec-
tomy for locally advanced bladder cancer were investi-
gated to compare the results of preoperative PET/CT
and conventional CT with the findings of postoperative
histopathological evaluation of LNs.
Methods
Patients
At our hospital, a total of 67 patients with urinary blad-
der cancer were scheduled for radical cystectomy with
pelvic LN dissection between 2010 and 2012. All these
patients underwent FDG-PET/CT and conventional CT
of the thorax and abdomen as part of pre-cystectomy
evaluation. Twelve of the patients did not have a cystec-
tomy for the following reasons: 4 had distant metastasis
(M1; positive in both conventional CT and PET/CT); 2
had ASA 4 and high surgical risk; 6 preferred radiation
therapy. One of the remaining 55 patients did undergo
radical cystectomy but had no LN dissection and was
therefore excluded from further analysis. All patients were
scheduled for FDG-PET/CT of the thorax and the abdo-
men 1 to 2 months before cystectomy. However, 6 patients
had undergone PET/CT more than 2 months before cyst-
ectomy, because the surgery had been delayed to perform
necessary investigations to address suspected distant me-
tastases. No patient had preoperative chemotherapy.
The use of PET/CT as an additional mode of investiga-
tion of candidates for cystectomy was initiated at our de-
partment as a routine procedure in all patients. The
method was considered to be safe and well established.
We studied herein if additional information could be
extracted from PET/CT in this particular setting. No
ethical consent was therefore considered to be necessary.
However, we had prior to the start of the investigation
an approval from The Regional Ethics Committee
(Reference number M42-08). We used oral informed
consent from the patients.
Equipment and imaging protocol
The patients scheduled for FDG-PET/CT fasted at least
4 h before injection of the FDG. Blood glucose was
monitored immediately before the injection, and a
level lower than 8 mmol/L was required to perform
the examination. The dose of FDG was 4 MBq/kg
body weight. Images were acquired 60 min after the
injection, and the patient drank 1 L of fluid or con-
trast medium during the 60-min interval between in-
jection and imaging. The examination was done using
a Siemens Biograph 40 PET/CT scanner with the pa-
tient in a dorsal recumbent position with the arms
above the head. Full-dose CT with IV contrast was
performed first, followed by PET (1.5–mm and 5–mm
slices and a resolution of 4.2 mm). CT was performed
using a thickness of 1.5 mm and a gap of 1.5 mm at
100 kV while mAS was regulated automatically ac-
cording to the volume of the patient.
The majority of the patients (88 %) had an indwelling
three-way catheter with bladder irrigation for continuous
evacuation of the bladder. In patients without such a
catheter, a renewed low-dose CT with PET was con-
ducted approximately 30 min after the start of the initial
imaging to detect PET-positive foci in the renal pelvis,
the ureters, or the bladder after evacuation of all ex-
creted FDG.
Image interpretation
The PET/CT images were evaluated by two radiologists
specialized and/or with extensive clinical experience in
PET/CT using axial, coronal and sagittal reconstruc-
tions. These experts performed the assessments inde-
pendently and without knowledge of operative or
postoperative data. In cases in which the results obtained
by the two radiologists were discordant, the investiga-
tions were mutually reviewed and discussed to reach
consensus. Kappa analysis showed good agreement
(Kappa value 0.85) between the PET/CT evaluations
conducted by the two radiologists. Conventional CT and
PET/CT were evaluated separately. The CT scans were
assessed without knowledge of the PET findings. Positive
LN findings were recorded for the following anatomical
regions used in clinical practice for pelvic LN dissection:
obturator fossa, external iliac, internal iliac, and com-
mon iliac. All PET images were evaluated by determining
the maximum standardized uptake value (SUV), using a
SUV-max cut-off of 2.5. LNs were considered to be posi-
tive by conventional CT if they had a diameter of ≥ 1 cm,
and positive by PET/CT if they exhibited higher levels of
activity than the SUV-max cut-off level regardless of their
size. No pathological LNs were found in the pelvis outside
the surgical templates. Distant metastases were suspected
when higher levels of radioactivity were found in other or-
gans, and in such cases evaluation was done to exclude
metastasis before surgery.
Surgery
Radical cystectomy was performed with a standardized
LN dissection. The upper limit of the LN dissection was
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at the level of the ureteric crossing of the common iliac
vein immediately cranial to confluence of the external
and internal iliac veins in 49 (91 %) patients and was ex-
tended to the aortic bifurcation in 5 patients. The deci-
sion to extend the dissection was made by the surgeon if
LN metastases were suspected based on the radiological,
clinical, or perioperative data. The dissection extended
down to the level of Cooper’s ligament, with the genito-
femoral nerve as the lateral boundary. Specimens from
the following four anatomical regions on both the right
and the left side were sent separately for pathological
examination: obturator, external iliac, and internal iliac,
as well as the common iliac in cases with dissection to
the aortic bifurcation. Each LN was sectioned in the
middle along the larger axis, and a single 4-μm slice was
mounted on a slide and stained with haematoxylin-eosin
before analysis.
Histopathological reevaluation
The specimens on the patients’ slides from cystectomy
and lymph node dissection material were all reevaluated
microscopically regarding T-stage, WHO grade, presence
of lymphovascular invasion, and LN metastasis. This re-
assessment was performed by an experienced uropathol-
ogist (HO). All positive nodes were completely or almost
completely infiltrated by bladder cancer.
Data analysis
Results of PET/CT, conventional CT, and histopatho-
logical examination were compared on three levels: first,
regarding positive or negative results in general for each
patient regardless of node localization; second, according
to the four anatomical regions; third, with respect to the
side of the body (right or left) of each patient’s LN
dissection. The third approach was applied because of
potential difficulties associated with evaluating an exact
anatomical region in both PET and surgery. Using the
histopathological examination as gold standard, each
PET/CT and conventional CT examination was classified
as true positive or false positive, and true negative or
false negative. The sensitivity, specificity, positive pre-
dictive value (PPV), and negative predictive value (NPV)
were calculated.
Results
Of the 54 evaluable patients, 50 (93 %) had urothelial
cancer and 4 (7 %) had non-urothelial cancer. Also, 40
(74 %) of the 54 patients had muscle-invasive tumors.
The mean time between PET/CT and surgery was 30
(6–133) days. Six patients had undergone PET/CT more
than 2 months before cystectomy, because the surgery
had been delayed for further investigations due to sus-
pected distant metastasis. In one of these 6 patients,
LNs were positive in histopathological examination but
negative by both PET/CT and conventional CT; for the
remaining 5 patients, all 3 investigations were negative.
Thus 54 patients were eligible for evaluation in our study,
47 men and 7 women (mean age 68 years, range 46–85
years). Considering all 54, histopathological examination
showed no LN metastasis (N0) in 37 (69 %) but revealed 1
or more positive LNs in 17 (31 %), and 16 (94 %) of those
17 patients had pT3-pT4 disease. FDG uptake was found
in 12 patients (22 %), and 7 of those observations were
confirmed by pathology. Conventional CT alone showed
enlarged LNs in 11 patients (20 %), which was confirmed
by pathology in 7 cases. Equivalent findings were obtained
by both PET/CT and conventional CT in 43 (80 %) of the
54 patients (Table 1). The following was observed in the
remaining 11 patients (20 %): 9 were positive by PET/CT
and negative by conventional CT, and only 1 of those find-
ings was confirmed by pathology; 2 were positive by con-
ventional CT and negative by PET/CT, and neither case
was confirmed by pathology.
At the first level of analysis, which considered the
whole patient, sensitivity was low for both PET/CT and
conventional CT (Table 2). At the second level of ana-
lysis, we investigated all 1,518 LNs (mean 28 nodes per





Male 14 33 47
Female 3 4 7
Age
Mean≤ 68y 6 22 28
Mean > 68 y 11 15 26
Clinical stage
cT1 1 8 9
cT2 6 21 10
cT3 10 7 16
cT4 0 1 14
Pathological stage
pT1 0 14 14
pT2 1 9 10
pT3 7 9 16
pT4 9 5 14
PET/CT
Positive 7 5 12
Negative 10 32 42
CT findings
Positive 7 4 11
Negative 10 33 43
Aljabery et al. BMC Urology  (2015) 15:87 Page 3 of 6
patient) excised from 347 sites in the stipulated anatom-
ical regions, and metastases were confirmed by path-
ology in 99 LNs (7 % of all LNs) from 55 (16 %) of the
347 sites. FDG-PET/CT was negative in 41 sites with
metastases, which was confirmed by pathology, whereas
conventional CT was negative in 48 sites with metasta-
ses. Also at this level of analysis, sensitivity was low for
both PET/CT and conventional CT (Table 2).
Thus there were difficulties in determining the exact
location of individual LNs in precise anatomical regions,
both during surgery and in radiological evaluation. Ac-
cordingly, in the third level of analysis, we considered
both the left and the right side of in each patient, which
showed low sensitivity for both PET/CT and conven-
tional CT (Table 2).
Discussion
In the present study, we compared FDG-PET/CT and
conventional CT regarding the rate of detection of posi-
tive LNs as standard investigation of all patients before
cystectomy, using histopathological examination of LNs
as the gold standard. We found low levels of sensitivity
for both FDG-PET/CT and conventional CT, which
agrees with the results obtained by Swinnen et al. [20].
However, the levels we observed are lower than those re-
ported by Drieskens et al, Liu et al, and Kibel et al, and
Goodfellow et al [21–24], who noted sensitivity rates
ranging from 60 to 77 % when using protocols for PET/
CT imaging and analyses similar to those employed in
our study. There is no obvious explanation for this dis-
crepancy, although most of the mentioned studies were
rather small, and hence only a few additional patients
with positive PET/CT results might have had a marked
impact on the rate of sensitivity.
Another plausible reason for differences in the LN de-
tection rate might be related to the extent of LN dissec-
tion. In our series, we used the level of the ureteric
crossing of the common iliac vein immediately cranial to
confluence of the external and internal iliac veins as the
upper limit of dissection in the majority of cases,
whereas extended dissection to the aortic bifurcation
was used in patients with clinical or radiological suspi-
cion of LN metastases. A similar approach was applied
by Kibel et al [22] with 70 % sensitivity. However,
Swinnen et al [20] performed dissection to the aortic
bifurcation in all patients and despite that observed
sensitivity rates comparable to those noted in our
series. These findings seem to suggest that the level of
LN dissection does not determine the rate of sensitivity
of PET/CT. Other investigators have discussed the
completeness of LN dissection in terms of the number
of extirpated LNs, using cut-offs of 16 and 20 LNs as
an indication of a complete dissection [6, 11]. In our
patients, a mean of 28 LNs were extirpated, which
might represent an acceptable level of completeness in
the dissection. Notably, studies of other comparable
series have not given any information about the num-
ber of LNs removed [21–25].
Optimally, PET/CT should detect a localized patho-
logical LN in order to enable regionally limited LN dis-
section [16, 20]. However, we found that sensitivity
decreased from 41 % on a patient level to 25 % on a re-
gional LN level, and Drieskens et al. [21] have also
noted a drop in sensitivity from 60 % to 50 % on the
regional level. Even though the indicated lower sensi-
tivity implies that PET/CT is not suitable for exact
localization of regional LN metastases, this hybrid
imaging technique might nonetheless be useful to
achieve improved tumor staging in individual patients,
particularly if it is performed in combination with per-
cutaneous biopsies [25]. Furthermore, PET/CT might
aid detection of pathological LNs outside the surgical
template. Although we did not find any pathological
LN outside the surgical template in our small series
this might be an advantage of PET/CT to limit LN
dissection as suggested by others [16, 20].
Employing novel tracers might also enhance detec-
tion of LN metastases. Orevi et al obtained promising
PET/CT results using 11C-choline to investigate 18
patients with bladder cancer [26], and Ahlström et al
reported 11C-methionine to be superior to FDG in this
context [27].
Table 2 Different levels of analysis of lymph nodes comparing
pathology results and results of conventional CT and PET/CT in
54 patients treated with cystectomy for locally advanced
bladder cancer
First level of analysis
Patho pos Patho neg Sensitivity Specificity PPV NPV
CT pos 7 4 41 % 89 % 64 % 77 %
CT neg - 10 33
PET pos+ 7 5 41 % 86 % 58 % 76 %
PET neg- 10 32
Second level of analysis
Patho pos Patho neg Sensitivity Specificity PPV NPV
CT pos 7 10 13 % 97 % 41 % 85 %
CT neg 48 282
PET pos 14 24 25 % 92 % 37 % 87 %
PET neg 41 268
Third level of analysis
Patho pos Patho neg Sensitivity Specificity PPV NPV
CT pos 9 5 31 % 94 % 64 % 79 %
CT neg 20 74
PET pos 11 14 38 % 82 % 44 % 78 %
PET neg 18 65
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Moreover, 2 recent studies have shown that PET/MRI
alone had a greater impact on clinical management com-
pared to PET/CT alone [28, 29]. However we are still
awaiting a systematic study PET/MRI in bladder cancer.
PET/CT has a number of limitations, and a potential
drawback of our study concerns the difficulty in localiz-
ing the exact site of pathological LNs both at surgery
and at PET/CT. The resolution of PET is inadequate
and needs to be improved to provide better images, al-
though tumor size was not a problem in our study as
the image resolution was 4.2 mm and all our positive
LNs were massively infiltrated with tumour cells [30].
Other potential weaknesses of our study include aspects
related to tumor biology, such as the degree of glucose
consumption, which varies considerably and is affected
by multiple factors [16]. A major drawback of FDG-
PET/CT is urinary elimination of FDG, which can be
only partly neutralized by using a bladder washing/rins-
ing system in combination with diuretic medication and
intravenous fluids [18]. It is possible that other isotopes
(e.g. 11C-methionine or 11C-choline) can be more use-
ful than FDG as the tracer in PET/CT investigation of
bladder cancer [26].
The design of our study also had some limitations. This
investigation comprising a small number of patients, and
hence no firm conclusions can be drawn from the results.
Furthermore, it was our intention to explore the possibility
of routine PET/CT for all patients undergoing cystectomy.
Considering the substantial number of PET/CT examina-
tions that were negative in our subjects, it might have
been more appropriate to study patients who were at
greater risk of having positive LNs. Our assessments relied
on pathological examination of single sections of LNs, and
it is possible that using step-sectioned nodes for compari-
son would have improved the sensitivity and specificity of
PET/CT. Finally, the time from PET/CT to surgery in our
study was too long in some cases, which might have influ-
enced the results.
Conclusions
This study showed that, compared to conventional CT,
FDG-PET/ CT provided no improvement in detection
and localization of regional LN metastases in bladder
cancer. Both these imaging approaches showed low sen-
sitivity in detecting LN metastases, and the sensitivity
decreased with a more exact degree of LN localization.
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